GEN Edge - Latest

Latest

Antibodies

AbCellera, Lilly Advance Next-Generation Antibody vs. COVID-19

Coronavirus

From Pandemic to Pipeline: What’s Next for Moderna?

Antibodies

Scholar Rock: A New Twist on Targeting Growth Factors

Cancer

Celularity: Productizing Placental-Derived Stem Cells for Any Patient

Drug Discovery

Zymergen Ready for Prime Time after $530M IPO

Artificial Intelligence

ELVIS Lives: 20th Century Inspires Drug Developer’s AI Tools

Autoimmune Disorders

A Ruby in the Rough: Rubius Therapeutics Transforms Red Blood Cells into Cellular Medicines

Artificial Intelligence

From Model to Molecule: NVIDIA Doubles Down on AI Drug Discovery

AgBio

Let There Be Light: GreenLight Strives for Global RNA Equity to Solve Health and Agricultural Problems

Coronavirus

Icosavax: Giving VLPs the VIP Treatment

CRISPR

Inscripta Eyes Broader Genome Editing Reach with $150M Series E

Drug Discovery

You Can See Manhattan from Your Lab: $3B “Cove” Campus Announced in Jersey City

Cancer

Epizyme Charts Five-Year Clinical Vision, Seeing Silver Linings Amid Tazverik Clouds

CRISPR

Doudna’s Scribe Rewrites CRISPR Drug Development with $100 Million Series B

Antibodies

Innate Immunity: French Biotech Builds Antibody Pipeline against Cancer

base editing

Feel That Base: An Interview with Base Editing Pioneer David Liu

Cancer

It’s a tRNA World: How aTyr Transformed tRNA Synthetases into Clinical Stage Medicines

Companies

Anima Biotech Heads for the Light with Up-to-$2.4B Takeda Partnership

Drug Discovery

Pain Drug Developer Approaches a Key In-Flexion Point

GEN Edge

Nanopore Sequencing: The Long and Winding Road

Financing

Tessera Rewrites the Genome Script Using Mobile Genetic Elements

Cancer

Caribou Rides RNA Wave with $115M Series C Financing

Commentary

Delivering on a Promise: The Present and Future of Targeted Protein Degradation

April 2021 Vol. 41 No. 4

OXGENE Eyes Further Growth in Cell and Gene Therapy Services after Acquisition by WuXi AppTec

Coronavirus

Breathe In: Theravance Reports Positive Phase II Data for JAK Inhibitor

Cancer

The Life Oncolytic, with Stephen Russell

10x Genomics

Flush with Cash, Foresite Aims to Live Up to Its Name

GEN Edge

From Genomes to Drugs: An Interview with Vertex CSO David Altshuler

AAV (Adeno-associated virus)

AI Gets Gene Therapy Over the Immunity Hump

Alzheimers

Immunai Expands from Observational to Functional Genomics